The Trial Remifentanil DEXmedetomidine (TREX) trial
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
This dataset contains individual level perioperative data collected for the short term outcomes analysis of the multicentre TREX phase III randomised controlled trial. Infants less than 2 years of age undergoing general anaesthesia expected to last at least 2 hours were randomised 1:1 to low dose sevoflurane plus dexmedetomidine and remifentanil (LD SEVO) or standard dose sevoflurane (STD SEVO). Data cover intraoperative haemodynamics, anaesthetic events, recovery metrics, pain scores, and morbidity and mortality through postoperative day 5. The dataset enables comparison of the safety and feasibility profiles of LD SEVO vs STD SEVO techniques in early childhood. Prior to releasing any data the following are required: a data access agreement must be signed between relevant parties, the TREX Trial Steering Committee must see and approve the analysis plan describing how the data will be analysed, there must be an agreement around appropriate acknowledgement and any additional costs involved must be covered. Data will only be shared with a recognised research institution which has approved the proposed analysis plan. IPD Sharing Supporting Information Type Study Protocol, Statistical Analysis Plan (SAP), Informed Consent Form (ICF), Clinical Study Report (CSR), Analytic Code DOI: 10.1097/ALN.0000000000005232
Fields of Study & Subjects
Anesthesia and Sedative Agents
Anesthesia and Pain Management
Veterinary Pharmacology and Anesthesia
Publication details
- Journal / source
- University of Melbourne data repository
- Publication date
- 26 March 2026
- Language
- EN
- Document type
- Dataset